• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Opinion
Video

Experts discuss future directions of BTK inhibitors.

Video content above is prompted by the following:

  • Let’s discuss anticipated (or just presented) data from ASCO 2024 on the treatment of CLL. What data or insights are you most looking forward to coming out of ASCO 2024?
  • How might emerging biomarkers influence the development and use of BTK inhibitors in CLL?
Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

May 1st 2025
Article

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

Read More

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024
Podcast

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

Triple combination therapy guided by MRD showed promise in R/R CLL. | Image credit: Matthieu - stock.adobe.com

MRD-Guided Triplet Therapy Leads to Deep Remissions in R/R CLL

April 28th 2025
Article

Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.

Read More

Acalabrutinib is a second-generation BTKi with reduced cardiovascular toxicity and an overall better safety profile compared with ibrutinib. | Image credit: Laszlo - stock.adobe.com

Acalabrutinib Combos Improve PFS vs CIT in First-Line CLL

April 20th 2025
Article

Acalabrutnib plus venetoclax, with or without obinutuzumab, improved progression-free survival (PFS) compared with chemoimmunotherapy (CIT) in patients with untreated chronic lymphocytic leukemia (CLL), meeting the phase 3 AMPLIFY study’s primary endpoint.

Read More

While pausing therapy did not affect response to vaccination, the investigators noted that participants who paused therapy did have higher rates of self-reported lymphadenopathy. | Image credit: Konstantin Yuganov - stock.adobe.com

Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

April 18th 2025
Article

Previous work had suggested pausing Bruton tyrosine kinase (BTK) inhibitors before COVID-19 vaccination might boost immunity in patients with chronic lymphocytic leukemia (CLL).

Read More

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

April 15th 2025
Article

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.